Comprehensive analysis of SYTL4 differential expression and clinical implications in DLBCL
Findings highlight the potential of SYTL4 as a promising diagnostic marker, prognostic biomarker, and therapeutic target in DLBCL patients and reveal interactions between SYTL4 and key regulators such as phosphatase and actin regulator 2 (PHACTR2), suggesting its potential role in DLBCL progression.